Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Lixte Biotechnology Holdings, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

539319 10 3

(CUSIP Number)

 

February 24, 2017

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

	[  ]	Rule 13d-1(b)
	[X]	Rule 13d-1(c)
	[  ]	Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

 

 

 

	1.	NAMES OF REPORTING PERSONS. Lalit Bahl
	2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [  ] (b) [X]
	3.	SEC USE ONLY
	4.	CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
				5.	SOLE VOTING POWER	0
				6.	SHARED VOTING POWER	4,000,000
				7.	SOLE DISPOSITIVE POWER	0
				8.	SHARED DISPOSITIVE POWER	4,000,000
	9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON. 4,000,000
	10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
	11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)[1] 8.35%
	12.	TYPE OF REPORTING PERSON   IN

¹       Based on 47,875,814 shares of common stock outstanding as of November 1, 2016, as reflected in the Issuer’s Form 10-Q for the quarter ended September 30, 2016.

 

 

	1.	NAMES OF REPORTING PERSONS. Kavita K. Kinra
	2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [  ] (b) [X]
	3.	SEC USE ONLY
	4.	CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
				5.	SOLE VOTING POWER	0
				6.	SHARED VOTING POWER	4,000,000
				7.	SOLE DISPOSITIVE POWER	0
				8.	SHARED DISPOSITIVE POWER	4,000,000
	9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON. 4,000,000
	10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
	11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)[2] 8.35%
	12.	TYPE OF REPORTING PERSON   IN

¹       Based on 47,875,814 shares of common stock outstanding as of November 1, 2016, as reflected in the Issuer’s Form 10-Q for the quarter ended September 30, 2016.

 

 

Item 1(a). Name of Issuer.

 

The name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).

 

Item 1(b). Address of Issuer’s Principal Executive Offices.

 

The address of the Issuer’s principal executive office is 248 Route 25A, No. 2, East Setauket, New York 11733.

 

Item 2(a). Name of Person Filing.

 

The names of the individuals are Lalit Bahl and Kavita K. Kinra (each a “Reporting Person”).

 

Item 2(b). Address of Principal Business Office, or, if None, Residence.

 

The address of Reporting Persons is c/o the Company, 248 Route 25A, No. 1, East Setauket, New York 11733.

 

Item 2(c). Citizenship.

 

Each of the Reporting Persons is a United States citizen.

 

Item 2(d). Title of Class of Securities.

 

The title of the class of securities to which this statement relates is the common stock of the Issuer, $0.0001 par value per share (the “Common Stock”).

 

Item 2(e). CUSIP No.

 

The CUSIP number is 539319103.

 

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check Whether the Person Filing is a:

 

(a)	[  ]	Broker or dealer registered under Section 15 of the Act
(b)	[  ]	Bank as defined in Section 3(a)(6) of the Act
(c)	[  ]	Insurance Company as defined in Section 3(a)(19) of the Act
(d)	[  ]	Investment Company registered under Section 8 of the Investment Company Act of 1940
(e)	[  ]	Investment Adviser registered under section 203 of the Investment Advisers Act of 1940
(f)	[  ]	Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
(g)	[  ]	Parent Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7)
(h)	[  ]	Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

 

Item 4. Ownership.

 

The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference. The Reporting Persons hold the securities as JTWROS.

 

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this Schedule is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	Dated: April 12, 2017
	/s/ LALIT BAHL
	Lalit Bahl

 

	/s/ KAVITA K. KINRA
	Kavita K. Kinra